KOSDAQBiotech & Pharma354200

NGeneBio

₩700▼ 5.41%2026-11-18 close
Market Cap
₩11.3B
Turnover
₩200M
Volume
350K
Shares out.
16.1M
PER
—
PBR
0.3×
EPS
-₩951
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Diagnostics Growth and Distribution Shift Amid Ongoing Losses

NGeneBio's revenue has risen for two straight quarters in 2026, but much of the growth came from the pharmaceutical distribution business it acquired, while operating losses and debt burden remain.

  1. 1

    Revenue for 2025 reached KRW 21.2 billion, up 273.2% from the prior year, while the operating loss narrowed to KRW 8.28 billion from KRW 16.1 billion in 2024.

  2. 2

    Third-quarter 2026 revenue rose to KRW 13.4 billion, the second straight quarterly gain, but the operating loss widened to KRW 1.31 billion from the prior quarter.

  3. 3

    Of roughly KRW 24.4 billion in first-half 2026 revenue, distribution accounted for about KRW 20.7 billion and diagnostics for about KRW 3.7 billion, according to the half-year report.

  4. 4

    Second-quarter 2026 diagnostics revenue was about KRW 1.35 billion, up 80.7% year on year, and overseas diagnostics revenue rose 102.1%, according to the company.

  5. 5

    The debt ratio (total liabilities to total equity) stood at 220.2% at the end of 2025, with liabilities of KRW 49.7 billion against equity of KRW 22.6 billion, making the balance sheet a key issue.

02

Business structure

NGeneBio supplies next-generation sequencing (NGS)-based cancer diagnostic panels and genomic analysis software to medical institutions, and it listed on KOSDAQ in 2020 through the technology special listing route. Diagnostics accounted for 97.7% of consolidated revenue as recently as 2024.

Its main products include the BRCAaccuTest for hereditary breast and ovarian cancer, the HEMEaccuTest for blood cancers, the SOLIDaccuTest for solid tumors, and the ONCOaccuPanel, a large panel covering more than 300 genes, along with the MRDaccuPanel AML FLT3 for detecting minimal residual disease in leukemia.

The company supplies its panels and analysis software to more than 30 medical institutions in Korea, including major tertiary hospitals, and to about 28 countries worldwide.

A pharmaceutical wholesaler acquired in November 2025 was merged into the company on March 31, 2026, and NGeneBio now runs a wholesale business supplying prescription drugs to pharmacies near Asan Medical Center and Samsung Medical Center.

Of consolidated first-half 2026 revenue of KRW 24.4 billion, distribution accounted for KRW 20.7 billion and diagnostics for KRW 3.7 billion, and the distribution share of consolidated revenue rose from 66.6% in 2025 to 84.7% in the first half of 2026.

The US subsidiary TOPLAB provides toxicology, molecular diagnostics and blood testing services. In July 2026, the company signed an official channel partnership with Illumina, extending its scope to high-capacity NGS instruments. Overseas sales are expanding from Southeast Asia and Europe into South Asia and the Middle East.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩5.4B-₩1.6B−30.3%
2025Q4₩12B-₩1.9B−15.9%
2026Q1₩12B-₩1.6B−13.1%
2026Q2₩12.5B-₩1.2B−9.5%
2026Q3₩13.4B-₩1.3B−9.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩11B-₩8.6B-₩9.8B−78.1%−38.7%121.8%
2023₩4.4B-₩13.4B-₩12.8B−308.6%−78.4%160.5%
2024₩5.7B-₩16.1B-₩12.6B−282.5%−74.4%86.1%
2025₩21.2B-₩8.3B-₩5.5B−39.0%−24.1%220.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

On a DART-filed basis, revenue fell from KRW 11 billion in 2022 to KRW 4.35 billion in 2023, a 60.5% decline, then rose to KRW 5.69 billion in 2024 and KRW 21.2 billion in 2025, marking two consecutive years of growth from 2024 through 2025. 2025 was the largest revenue year of the 2022 to 2025 period.

According to the company, the increase reflected strong domestic and overseas sales of its NGS panels and analysis software, plus the consolidation of the pharmaceutical wholesaler acquired in November 2025, and distribution revenue in 2025 was KRW 14.1 billion, or 66.6% of annual revenue.

The operating loss widened from KRW 8.6 billion in 2022 to KRW 13.4 billion in 2023 and KRW 16.1 billion in 2024, then narrowed to KRW 8.28 billion in 2025, extending a loss streak that runs four consecutive years from 2022 through 2025.

The operating margin moved from -78.1% in 2022 to -308.6% in 2023 and -282.5% in 2024, then improved to -39.0% in 2025, an improvement that appears driven largely by the larger revenue base.

Net loss attributable to controlling shareholders was KRW 9.79 billion in 2022, KRW 12.8 billion in 2023, KRW 12.6 billion in 2024 and KRW 5.54 billion in 2025. The net loss including non-controlling interests was KRW 6.76 billion in 2025, larger than the loss attributable to controlling shareholders.

Operating cash flow was negative in all four years, at -KRW 7.82 billion in 2022, -KRW 9.17 billion in 2023, -KRW 12.4 billion in 2024 and -KRW 8.48 billion in 2025.

On a quarterly basis, revenue in the fourth quarter of 2025 rose 120.5% from the prior quarter to KRW 12 billion, and third-quarter 2026 revenue of KRW 13.4 billion was up 147.5% year on year.

In the fourth quarter of 2025, the company swung to a profit attributable to controlling shareholders of KRW 4.48 billion despite an operating loss of KRW 1.9 billion, suggesting non-operating items were large, and whether that gain was one-off is the next point to check.

Attributable net losses continued in each quarter from the first quarter through the third quarter of 2026, and the four-quarter total from the fourth quarter of 2025 through the third quarter of 2026 was KRW 6.62 billion.

05

Industry analysis

NGeneBio sits among diagnostics companies that supply NGS panels together with analysis software. In July 2026 the company signed an official channel partnership with Illumina, and it is trying to widen hospital adoption through an 'NGS total solution' that includes instruments.

Its stated strategy is to build a recurring revenue base in which panels and consumables are supplied after an instrument is installed.

Overseas, the company has kept long-term panel supply to its core Southeast Asian and European markets while expanding into South Asia and the Middle East, and the share of new-market revenue rose from 6.1% in the second quarter of 2025 to 34.6% in the second quarter of 2026, according to the company.

Its breast and ovarian cancer diagnostic panel became the first in Korea to receive CE-IVDR certification in Europe. The company argues that existing global genomic databases are weighted toward Western populations, which raises the value of Asian genomic data, and it is expanding its data business on that basis.

Unlike Samsung Biologics or Celltrion, which center on contract manufacturing or biologics development, NGeneBio combines diagnostic panels, software and a distribution subsidiary, so direct comparison of sector-level metrics is limited.

Competition is likely to turn on whether a supplier can deliver instruments, panels and software as one package.

06

Outlook

For the second half of 2026, the company plans to expand hospital adoption of its NGS total solution and strengthen its recurring revenue base, as announced on August 14, 2026.

Its AI pathology analysis software NPAS is being prepared for commercialization on the basis of an LG AI Research model, and the plan also includes research collaboration with pharmaceutical companies on drug development and an integrated AI and NGS companion diagnostics business.

The company also plans to increase the number of institutions using its genome information management system by year-end.

On November 13, 2026, it announced that a clinical performance study of its minimal residual disease detection technology for FLT3-ITD leukemia had been published in an international journal, and it intends to use the results for overseas regulatory approvals and wider supply to global medical institutions.

Overseas, it aims to expand sales of its blood cancer, hereditary cancer and solid tumor panels. On the funding side, the board approved a third-party allocation rights issue to the largest shareholder on November 10, 2026.

Press reports differ, with some citing KRW 8 billion for 8 million shares and others KRW 6 billion for 6 million shares, so the official filing is the next point to confirm. The same day, the company agreed to acquire 100% of a solar EPC firm for KRW 2 billion, with the balance due on November 23, 2026.

A solar power plant construction project in Gangwon Province held by that unit is scheduled for completion at the end of December 2026, and direct ownership and operation of plants is under review.

A December 21, 2026 extraordinary shareholders' meeting has an agenda item to appoint the head of the acquired unit as an inside director.

07

Valuation

PER
—
PBR
0.3×
ROE
-33.8%
EPS
-₩951
BPS
₩2,514
Dividend per share
₩0

The price-to-book level sits well below the book value of equity, meaning the share price is trading at a steep discount to net assets. However, with total equity of KRW 22.6 billion against total liabilities of KRW 49.7 billion at the end of 2025, the cushion provided by net assets is thin.

Because the company has posted net losses over the last four quarters, a price-to-earnings multiple cannot be calculated. No dividends are paid, so a dividend-based comparison does not apply. Behind the low price relative to net assets are continued losses, a high debt ratio and repeated fundraising.

In June 2026 the company carried out a reverse stock split that merged three shares into one, and subsequent rights offerings have sharply increased the number of listed shares. The Korea Exchange separately assesses whether rights-adjusted companies fall below the market capitalization threshold under its rules.

The key question for valuation is whether the reduction in operating losses continues quarter after quarter and whether the debt structure improves.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Fast growth in overseas diagnostics sales

According to the company, second-quarter 2026 diagnostics revenue was about KRW 1.35 billion, up 80.7% year on year, and overseas diagnostics sales rose 102.1%. Sales of the blood cancer panel abroad increased 114%, and new markets in South Asia and the Middle East rose to 34.6% of revenue. The CE-IVDR certification in Europe is cited as a base for overseas expansion.

A trend of narrowing losses

The operating loss narrowed from KRW 16.1 billion in 2024 to KRW 8.28 billion in 2025, and the operating margin improved from -282.5% to -39.0%. On a quarterly basis, the operating loss of KRW 1.19 billion in the second quarter of 2026 was smaller than KRW 1.57 billion in the first quarter. Operating cash outflow also shrank to -KRW 8.48 billion in 2025 from -KRW 12.4 billion in 2024.

Expanding detection technology and platform

In a study the company announced, the FLT3-ITD positive detection rate for minimal residual disease was 60.1%, against 17.2% for an existing test. In samples in complete remission before stem cell transplant, the rate was 65.3% versus 14.5% for the existing method.

A domestic patent for the related algorithm has been registered, and the Illumina partnership gives the company a package spanning instruments to analysis software.

09

Bear factors

Persistent operating losses

The operating loss has been recorded in four consecutive years from 2022 through 2025, and in five consecutive quarters from the third quarter of 2025 through the third quarter of 2026. The third-quarter 2026 operating loss of KRW 1.31 billion widened from KRW 1.19 billion in the prior quarter.

Losses attributable to controlling shareholders continued for three straight quarters from the first quarter through the third quarter of 2026, with a four-quarter total of KRW 6.62 billion.

Financial strain and share dilution

The debt ratio rose to 220.2% at the end of 2025 from 86.1% in 2024, with liabilities of KRW 49.7 billion against equity of KRW 22.6 billion. According to the half-year report for 2026, a KRW 25 billion sixth series convertible bond remained outstanding.

In 2026 the company completed a reverse split followed by rights offerings that raised about KRW 7.7 billion, and in November it approved a rights issue to its largest shareholder, with press reports citing sizes of KRW 8 billion and KRW 6 billion.

Composition of revenue growth

Of first-half 2026 revenue of KRW 24.4 billion, distribution accounted for about KRW 20.7 billion, and diagnostics for about KRW 3.7 billion. The distribution share of consolidated revenue rose from 66.6% in 2025 to 84.7% in the first half of 2026.

Revenue has grown through distribution, while the diagnostics contribution has become relatively smaller. How profit is split between segments is the next point to confirm in the periodic reports.

10

Risk factors

Funding and share dilution

Reverse splitting and rights offerings in 2026 have sharply increased the number of listed shares. The November 10, 2026 resolution for a rights issue to the largest shareholder leaves room for further dilution.

The stock was also designated for one day as an investment caution stock on November 11, 2026 after a sharp closing-price move, indicating high price volatility.

Litigation and disputes

A patent transfer registration suit filed by the Korea Tuberculosis Association is pending at the Seoul Central District Court. An arbitration request over severance and other payments to a former head of the US subsidiary NGeneBioAI is also in progress.

Financial and business effects could vary with the outcome, so the court ruling and arbitration result are the next points to confirm.

Execution of new businesses

The solar EPC company being acquired was established in January 2026, and its only confirmed project is a power plant construction contract in Gangwon Province. That project is scheduled for completion at the end of December 2026, while follow-on orders and plant operating income remain under review.

The company itself has said it focused on construction revenue and plant operating income rather than a direct link to its diagnostics business, so any synergy with the core business is uncertain.

11

What to watch next

  1. November 23, 2026

    The balance payment date for the acquisition of the solar EPC unit, and the first KRW 2 billion tranche of the rights issue is due for debt repayment. Completion of the acquisition and the use of funds are the next points to confirm.

  2. December 21, 2026

    An extraordinary shareholders' meeting will decide whether the head of the acquired unit is appointed as an inside director. Whether the new business management joins the board is the point to check.

  3. End of December 2026

    The scheduled completion of the solar plant construction in Gangwon Province falls in this period. Progress toward expanding institutions using the genome information management system, a target for the same period, is also a point to check.

  4. End of March 2027 (deadline for the annual business report)

    The 2026 annual business report will be filed. The 2026 operating loss, the loss attributable to controlling shareholders, whether the fourth-quarter 2025 profit swing was one-off, and the debt ratio are the points to confirm.

  5. April 1, 2027

    Reported as the second payment date of the rights issue resolved on November 10, 2026. Press reports cite different sizes, KRW 8 billion and KRW 6 billion, so checking the payment amount in the original filing is the next point to confirm.

12

Overall view

NGeneBio's recent trend has two sides. In diagnostics, second-quarter 2026 diagnostics revenue rose 80.7% year on year, and its overseas customer base widened. On an annual basis, the 2025 operating loss narrowed to KRW 8.28 billion from 2024, so the profit structure is moving in a better direction.

In contrast, the third-quarter 2026 operating loss widened from the prior quarter, and losses attributable to controlling shareholders continued for three straight quarters.

Revenue growth has been driven largely by the consolidation of a pharmaceutical distribution subsidiary, and diagnostics accounted for roughly 15% of first-half 2026 revenue, according to the company.

On the financial side, the debt ratio rose to 220.2% at the end of 2025, and unredeemed convertible bonds and repeated fundraising add to the burden.

The solar EPC acquisition and the leukemia residual disease detection study were presented as new growth pillars, but their contribution to earnings has not yet been confirmed.

The next points to confirm are the use of funds on November 23, 2026, the December 21, 2026 shareholders' meeting, and the operating loss and debt ratio in the 2026 annual business report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. ngenebio.com
  2. dailian.co.kr
  3. etoday.co.kr
  4. view.asiae.co.kr
  5. biz.heraldcorp.com
  6. biobookmedia.com
  7. newsway.co.kr
  8. view.asiae.co.kr
  9. kpanews.co.kr
  10. m.news.nate.com
  11. medifonews.com
  12. view.asiae.co.kr
  13. sisamagazine.co.kr
  14. topstarnews.net
  15. view.asiae.co.kr
  16. m.news.nate.com
  17. m.news.nate.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis